{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fmedicalspecialtiespodcast.simplecast.com%2Fepisodes%2Ftargeting-risk-beyond-lipids-sVTbMUto","width":444,"version":"1.0","type":"rich","title":"Expert Discussions: Moving Beyond Lipid Lowering to Lower Risk in ASCVD and CKD","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/9ebff3e7-1de9-4b33-a360-481c8997daad/7678-pod2-targeting-risk-beyond-lipids-3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/85d7afa5-37d5-4b28-bbca-4587ca477e37\" height=\"200\" width=\"100%\" title=\"Expert Discussions: Moving Beyond Lipid Lowering to Lower Risk in ASCVD and CKD\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Join us for this podcast episode with cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss the pathophysiology and novel therapeutic approaches to target residual inflammatory risk in patients with ASCVD and CKD. "}